131 related articles for article (PubMed ID: 7888674)
1. Role of endogenous cytokines secretion in radioprotection conferred by the immunomodulator ammonium trichloro(dioxyethylene-0-0')tellurate.
Kalechman Y; Zuloff A; Albeck M; Strassmann G; Sredni B
Blood; 1995 Mar; 85(6):1555-61. PubMed ID: 7888674
[TBL] [Abstract][Full Text] [Related]
2. Induction of acute phase proteins in mice and humans by treatment with AS101, an immunomodulator with radioprotective properties.
Kalechman Y; Shani A; Albeck M; Sredni B
Immunopharmacology; 1995 Mar; 29(2):149-58. PubMed ID: 7539780
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of radioprotection conferred by the immunomodulator AS101.
Kalechman Y; Gafter U; Barkai IS; Albeck M; Sredni B
Exp Hematol; 1993 Jan; 21(1):150-5. PubMed ID: 8417951
[TBL] [Abstract][Full Text] [Related]
4. Radioprotective effects of the immunomodulator AS101.
Kalechman Y; Albeck M; Oron M; Sobelman D; Gurwith M; Seghal SN; Sredni B
J Immunol; 1990 Sep; 145(5):1512-7. PubMed ID: 2384668
[TBL] [Abstract][Full Text] [Related]
5. Effect of the immunomodulator AS101 on chemotherapy-induced multilineage myelosuppression, thrombocytopenia, and anemia in mice.
Kalechman Y; Rushkin G; Nerubay J; Albeck M; Sredni B
Exp Hematol; 1995 Dec; 23(13):1358-66. PubMed ID: 7498364
[TBL] [Abstract][Full Text] [Related]
6. The immunomodulator AS101 administered orally as a chemoprotective and radioprotective agent.
Sredni B; Albeck M; Kazimirsky G; Shalit F
Int J Immunopharmacol; 1992 May; 14(4):613-9. PubMed ID: 1521929
[TBL] [Abstract][Full Text] [Related]
7. Protection of bone marrow stromal cells from the toxic effects of cyclophosphamide in vivo and of ASTA-Z 7557 and etoposide in vitro by ammonium trichloro(dioxyethylene-O-O')tellurate (AS101).
Kalechman Y; Sotnik-Barkai I; Albeck M; Sredni B
Cancer Res; 1993 Apr; 53(8):1838-44. PubMed ID: 8467503
[TBL] [Abstract][Full Text] [Related]
8. Increased DNA repair ability after irradiation following treatment with the immunomodulator AS101.
Kalechman Y; Shani A; Albeck M; Sotnik Barkai I; Sredni B
Radiat Res; 1993 Nov; 136(2):197-204. PubMed ID: 8248476
[TBL] [Abstract][Full Text] [Related]
9. The protective role of ammonium trichloro(dioxoethylene-O,O')tellurate in combination with several cytotoxic drugs acting by different mechanisms of action.
Kalechman Y; Shani A; Sotnik-Barkai I; Albeck M; Sredni B
Cancer Res; 1993 Dec; 53(24):5962-9. PubMed ID: 8261410
[TBL] [Abstract][Full Text] [Related]
10. Restoration of murine cytomegalovirus (MCMV) induced myelosuppression by AS101.
Sredni B; Rosenthal-Galili Z; Michlin H; Sobelman D; Seger Y; Blagerman S; Kalechman Y; Rager-Zisman B
Immunol Lett; 1994 Dec; 43(3):159-65. PubMed ID: 7721328
[TBL] [Abstract][Full Text] [Related]
11. The effect of AS101 on the reconstitution of T-cell reactivity following irradiation or cyclophosphamide treatment.
Kalechman Y; Sotnik-Barkai I; Albeck M; Sredni B
Exp Hematol; 1992 Dec; 20(11):1302-8. PubMed ID: 1493859
[TBL] [Abstract][Full Text] [Related]
12. In vivo synergistic effect of the immunomodulator AS101 and the PKC inducer bryostatin.
Kalechman Y; Albeck M; Sredni B
Cell Immunol; 1992 Aug; 143(1):143-53. PubMed ID: 1623562
[TBL] [Abstract][Full Text] [Related]
13. Protective and restorative role of AS101 in combination with chemotherapy.
Kalechman Y; Albeck M; Oron M; Sobelman D; Gurwith M; Horwith G; Kirsch T; Maida B; Sehgal SN; Sredni B
Cancer Res; 1991 Mar; 51(5):1499-503. PubMed ID: 1997189
[TBL] [Abstract][Full Text] [Related]
14. Use and mechanism of action of AS101 in protecting bone marrow colony forming units-granulocyte-macrophage following purging with ASTA-Z 7557.
Kalechman Y; Barkai IS; Albeck M; Horwith G; Sehagl SN; Sredni B
Cancer Res; 1991 Oct; 51(20):5614-20. PubMed ID: 1913679
[TBL] [Abstract][Full Text] [Related]
15. Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention.
Kalechman Y; Gafter U; Gal R; Rushkin G; Yan D; Albeck M; Sredni B
J Immunol; 2002 Jul; 169(1):384-92. PubMed ID: 12077268
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of the immunomodulator AS101 on B7-1 and B7-2 costimulatory molecules: role in the antitumoral effects of AS101.
Kalechman Y; Sredni B
J Immunol; 1996 Jul; 157(2):589-97. PubMed ID: 8752906
[TBL] [Abstract][Full Text] [Related]
17. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels.
Kalechman Y; Gafter U; Da JP; Albeck M; Alarcon-Segovia D; Sredni B
J Immunol; 1997 Sep; 159(6):2658-67. PubMed ID: 9300685
[TBL] [Abstract][Full Text] [Related]
18. Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101.
Sredni B; Tichler T; Shani A; Catane R; Kaufman B; Strassmann G; Albeck M; Kalechman Y
J Natl Cancer Inst; 1996 Sep; 88(18):1276-84. PubMed ID: 8797767
[TBL] [Abstract][Full Text] [Related]
19. The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma.
Kalechman Y; Shani A; Dovrat S; Whisnant JK; Mettinger K; Albeck M; Sredni B
J Immunol; 1996 Feb; 156(3):1101-9. PubMed ID: 8557985
[TBL] [Abstract][Full Text] [Related]
20. Ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop.
Sredni B; Weil M; Khomenok G; Lebenthal I; Teitz S; Mardor Y; Ram Z; Orenstein A; Kershenovich A; Michowiz S; Cohen YI; Rappaport ZH; Freidkin I; Albeck M; Longo DL; Kalechman Y
Cancer Res; 2004 Mar; 64(5):1843-52. PubMed ID: 14996748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
